Skip to content
‹ Back to IndustriesHealthcare

Joan Oloff is Making Fashion More Functional

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In a fashion landscape dominated by established brands, it can be difficult for a start-up to stand out. By providing customers with clothing and accessories that look great but can also be worn on the job, new brands are able to break through this barrier.

Few designers exemplify this innovative spirit as much as Joan Oloff. A podiatrist by training, Joan set out to make the first line of orthopedically correct high heels. After seeing the issues that traditional high heels cause in her patients, Joan knew there had to be a way to design beautiful shoes that wouldn’t negatively impact the health of the wearer’s feet down the road.

The challenge was taking elements already common in athletic and walking shoes, like offloading pressure points, incorporating shock-absorption and providing proper support, and finding a way to implement these same features in heels. Over the course of four years, Joan worked with designers and manufacturers, in both Los Angeles and Italy, to make her line of shoes fit her standards. It was difficult. The manufacturers didn’t want to do things her way. But she pushed ahead.

“If I’m not going to be a game-changer, if I’m not going to disrupt the way high heels are made, there’s no point for me to do this,” Joan said in an interview with the San Francisco Chronicle.

Her perseverance paid off and today, Joan Oloff’s shoes have built-in arch support, cushioning material in the ball of the foot and a lower heel pitch, all of which allow the entire foot to comfortably share the body’s weight. Perhaps the most impressive aspect of her line is simply the diversity of options. Made by hand, the latest collection has everything from sandals to knee-high boots. The beauty of the line, combined with the comfort of the shoes, have garnered Joan a loyal following. One surgeon in Santa Fe owns ten pairs of the shoes as they allow her to work without discomfort be it in her office, visiting patients or even conducting an hours-long surgical procedure.

While her customers all praise her shoes, Joan also has proof to back up her claims that she makes healthy heels. Using CurveBeam’s revolutionary pedCAT technology, Joan is able to show weight-bearing CT scans of her shoes in action. When compared side-by-side with the same scans of someone wearing standard heels, it is obvious that Joan’s shoes provide evenly distributed support and stable positioning while other shoes have toe crimping and no arch support, creating a painful experience for the wearer.

Just like Joan Oloff, CurveBeam is dedicated to changing the game. By creating innovative 3D scanning technology that provides a complete view of a patient’s lower extremities, the pedCAT has given podiatrists, physical therapists, and others the ability to give their patients the proper treatment they need. Learn more about pedCAT here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512